There are some short-lived, common adverse events for patients using cannabis, but also some more dangerous, less common ones in chronic users, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
Patients with cancer using cannabis may experience adverse events that range from common and short lived to less common and dangerous, explained Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic. However, products coformulated with cannabidiol (CBD) will dampen the psychoactive effects of tetrahydrocannabinol (THC), allowing patients to function better, she noted.
Transcript
What is important to know about the common and less common adverse events of cannabis in patients with cancer and how to manage them?
[With] some of the more common adverse effects, the nice thing about them is that they're usually short lived and pretty transient. You can see some dizziness, you can see some drowsiness, you can see the classical euphoria. Sometimes you can get some rebound anxiety if the THC dose is too high. Sometimes you could get a lingering headache if the THC dose is too high.
Then there's some of the lesser common ones that maybe are a little bit more dangerous—like the rebound media and depression, if you have chronic users who all of a sudden, abruptly stop using it. You can also see almost a cyclic vomiting syndrome in folks who also do that, they'll use it pretty chronically and then abruptly stop. I've seen folks go to the emergency room for that. So those are things I kind of watch out for.
For patients, what's interesting is, if you have products that are coformulated with CBD, it will kind of dampen those psychoactive effects of THC, but not take away the clinical benefit. If I have patients who are interested in maybe helping with pain or helping with sleep, but they don't want to feel high all the time, I recommend a product that’s coformulated with CBD and that will take away that stoned feeling and allow them to function day to day much better. I offer that as a means of mitigating some of the side effects that may be less desirable.
What do we consider chronic use of cannabis?
Daily use [of] normally a dose of over 5 milligrams or more. It's a little hard to quantify milligram doses when you're talking about inhaled products, but with the edible products, it's getting easier to quantify how much people are using. So that is, traditionally, what would be considered chronic use.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Frameworks for Advancing Health Equity: Youth Behavioral Health Strategy Program
September 17th 2024Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More